# A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC

Source: https://onco.cc/trials/nct07206498/  
OnCo record `nct07206498` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Osimertinib in non-small-cell lung cancer and small-cell lung cancer, run by Wayshine Biopharm, Inc., now recruiting.

## Summary

A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC is a phase 1/2 interventional study registered as NCT07206498 by Wayshine Biopharm, Inc., with 48 participants planned, started 2025-10-17 and due to reach its primary completion in 2028-10-14. Interventions recorded: Osimertinib (Tagrisso®), WSD0922-FU. Conditions listed: Non Small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07206498
- Phase: 1/2
- Setting: A Phase I/II Study to Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of WSD0922-FU in Combination With Osimertinib for Patients With Locally Advanced or Metastatic Non- Small Cell Lung Cancer
- Sponsor: Wayshine Biopharm, Inc.
- Enrolled: 48

## Sources

- ClinicalTrials.gov NCT07206498: https://clinicaltrials.gov/study/NCT07206498

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Osimertinib](https://onco.cc/drugs/osimertinib/)

---
JSON: https://onco.cc/api/v1/entities/nct07206498.json